Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 294-302

  Feld, Jordan J ^a,p   Jacobson, Ira M ^b   Jensen, Donald M ^c   Foster, Graham R ^d   Pol, Stanislas ^e   Tam, Edward ^f   Jablkowski, Maciej ^g   Berak, Hanna ^h   Vierling, John M ⁱ   Yoshida, Eric M ^j   Perez Gomez, Héctor R ^k   Scalori, Astrid ^l   Hooper, Gregory J ^l   Tavel, Jorge A ^m   Navarro, Mercidita T ^m   Shahdad, Saba ^l   Kulkarni, Rohit ^m   Pogam, Sophie Le ⁿ   Nájera, Isabel ^o   Eng, Simon ^m   Lim, Chin Yin ^m   Shulman, Nancy S ^m   Yetzer, Ellen S ^m   more..

^a McLaughlin Rotman Centre for Global Health   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e université Paris Cité   (France)

^f LAIR Centre   (Canada)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY OF GUADALAJARA   (Mexico)

^l ROCHE PRODUCTS LTD   (United Kingdom)

^m GENENTECH INC   (United States)

ⁿ HOFFMANN LA ROCHE INC   (United States)

^o F HOFFMANN LA ROCHE LTD   (Switzerland)

^p TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

Danoprevir; Genotype 1; Mericitabine; Non responders; Peginterferon ribavirin; Quad therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; DANOPREVIR; HEMOGLOBIN; MERICITABINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; RITONAVIR; ALPHA INTERFERON; CYTOCHROME P450 3A INHIBITOR; DRUG CARRIER; LACTAM; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; SULFONAMIDE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LACTAMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84922250521     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.013     Document Type: Article

References (28)

1. Rajagopalan R, Misialek S, Stevens SK, Myszka DG, Brandhuber BJ, Ballard JA, et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 2009; 48: 2559-2568.
2. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011; 53: 1090-1099.
3. Everson G, Cooper C, Hézode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, et al. DAUPHINE: A randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int 2014. http://dx.doi.org/10.1111/liv. 12471, [Epub ahead of print].
4. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013; 145: 790-800.
5. Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 972-979.
6. Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 2012; 17: 411-423.
7. Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int 2014. http://dx.doi.org/10.1111/liv.12588, [Epub ahead of print].
8. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, et al. JUMP-C: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 2013; 58: 514-523.
9. Wedemeyer H, Jensen D, Herring Jr R, Ferenci P, Ma MM, Zeuzem S, et al. PROPEL: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV Genotype 1/4 patients. Hepatology 2013; 58: 524-537.
10. Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-1519.
11. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
12. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221.
13. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatmentnaive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomized, phase 2 trial. Lancet 2013; 383: 515-523.
14. Jacobson IM, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study (abstract). Hepatology 2013; 58: 1379-1380A.
15. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT- 450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982.
16. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 31: 1207-1217.
17. Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan B, et al. Efficacy and safety of danoprevir/ritonavir plus peginterferon alfa-2aribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother 2014; 58: 1136-1145.
18. Margeridon-Thermet S, Le Pogam S, Li L, Liu TF, Shulman N, Shafer RW, et al. Similar prevalence of low-abundance drug-resistant variants in treatmentnaive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing. PLoS One 2014; 9: E105569.
19. Sulkowski M, Jacobson IM, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS- 7977) with or without ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis (abstract 07). J Hepatol 2014; 60: S4.
20. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST- 1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413.
21. Ma H, Le Pogam S, Fletcher S, Hinojosa-Kirschenbaum F, Javanbakht H, Yan JM, et al. Intracellular effects of the hepatitis C virus nucleoside polymerase inhibitor RO5855 (mericitabine parent) and ribavirin in combination. Antimicrob Agents Chemother 2014; 58: 2614-2625.
22. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444.
23. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-524.
24. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034-7039.
25. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563.
26. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, et al. Hepatic celltype specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142: 1122-1131.
27. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
28. Schaefer CJ, Kossen K, Lim SR, Lin JH, Pan L, Bradford W, et al. Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2011; 55: 3125-3132.